Additionally, treatments such as pioglitazone, SGLT2 inhibitors (SGLT2i), and GLP-1 receptor agonists (GLP-1RA) have proven effective in halting the progression of NAFLD in SIRD [35]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.